FDA rejects Avedro's ophthalmic drug-device
This article was originally published in Scrip
Executive Summary
The FDA has rejected Avedro's riboflavin ophthalmic solution/KXL System, which the company has been developing for keratoconus, a rare potentially blinding disease, and corneal ectasia, a rare outcome of refractive surgery, such as LASIK.